Needham & Company
-
Needham on Lucid (LUCD): 'we remain positive on potential Medicare reimbursement of EsoGuard and we expect LUCD's revenue growth to improve'
-
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
Lucid Diagnostics to Participate in Upcoming Investor Conferences
-
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
Needham reiterates Buy on Lucid Diagnostics (LCUD) following investor day
-
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
-
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
-
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
-
Lucid Diagnostics Inc (LUCD) PT Lowered to $7 at Needham & Company
-
Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
-
Lucid Diagnostics Inc (LUCD) PT Lowered to $13 at Needham & Company
-
UPDATE: Needham & Company Starts Lucid Diagnostics Inc (LUCD) at Buy
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics (LUCD) IPO Opens, Trades Lower
-
Lucid Diagnostics Inc (LUCD) Prices 5M Share IPO at $14/sh
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics (LUCD) IPO: 7 Things to Know

